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TITLE 
Hepatitis C in a new therapeutic era: Recontextualising the lived experience 
 
ABSTRACT 
Aims and Objectives: To explore the experience of adults living with hepatitis C in a new era of 
interferon-free treatment. 
Background: Hepatitis C is a leading cause of morbidity and mortality worldwide, posing a 
significant challenge to global public health.  Historically, the treatment of hepatitis C was poorly 
efficacious and highly demanding, however, more effective and tolerable therapies have become 
available in high-income nations in recent years.  This is the first study to explore how these 
significant developments in the treatment of hepatitis C may have influenced the experience of 
those living with the virus, and their understanding of the disease. 
Design: A qualitative study underpinned by social phenomenological theory. 
Methods: Data were generated through semi-structured interviews with a purposive sample of 20 
hepatitis C positive adults living in a large city in Scotland.   
Results: Thematic analysis identified three over-riding themes.  ‘Positioning hepatitis C’ illustrated 
how the disease was understood within wider sociocultural, medical and politico-economic 
contexts.  ‘Beyond a physical burden’ emphasised the emotional aspect of infection, and ‘a new 
uncertainty’ revealed participants’ cautious response to the advances in hepatitis C therapy. 
Conclusions: Inter-thematic discourse portrayed the new era of hepatitis C treatment as holding 
little sway over constructions of the illness, as narratives resonated with previous studies.  Such 
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unmoving ‘lay’ understandings of hepatitis C may pose potential barriers to the new therapeutic 
era from reaching its full potential. 
Relevance to clinical practice: How people living with the virus perceive and understand hepatitis C 
can have an adverse impact on their engagement with care and treatment.  Whilst global medical 
discourse eulogises the arrival of a new era of therapy, there remain significant challenges for 
nurses engaging those with hepatitis C in therapeutic pathways. 
 
SUMMARY BOX 
What does this paper contribute to the wider global community? 
- This paper provides the first exploration of how individuals living with hepatitis C are 
experiencing an interferon-free era of therapy. 
- The arrival of interferon-free treatments in clinical practice has yet to challenge societal 
constructions and understandings of hepatitis C. 
- The emergence of treatment rationing provides fresh challenges for engaging 
disenfranchised hepatitis C populations in care. 
 
KEYWORDS 
Direct-acting antivirals, Hepatitis C, interferon-free treatment, lived experience, social 
phenomenology, thematic analysis, treatment rationing 
 
INTRODUCTION 
The hepatitis C virus (HCV) is a leading cause of mortality and morbidity worldwide, posing a major 
challenge to global public health (World Health Assembly, 2016).  The virus is acquired through 
exposure to infected blood, and whilst the spontaneous resolution of acute infection is possible, 
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long-term infection occurs in approximately 60-85% of cases.  Chronic HCV is characterised by 
slowly progressing liver fibrosis, which leads to the development of cirrhosis in approximately 10-
20% of patients (Westbrook and Dusheiko, 2014).  Injecting drug use is the cause of a substantial 
proportion of the global burden of HCV disease, with injecting drug use-attributable HCV highest 
in high-income nations (Degenhardt et al., 2016).  Within the UK, the most recent national 
estimates suggest around 214,000 individuals are infected, of which approximately 37,000 reside 
in Scotland (Public Health England, 2015).   
 
BACKGROUND 
For over 15 years, recurrent qualitative investigation has illuminated how HCV is experienced, 
understood and constructed by those living with the virus.  Studies commonly portray a disruptive 
and distressing phenomenon manifest in social, emotional and physical spheres of illness, with 
specific facets of experience such as diagnosis (Glacken et al., 2001), fatigue (Glacken et al., 2003; 
Zalai et al., 2016) and stigma (Butt et al., 2008; Fraser and Treloar, 2006) often emphasised.  This 
body of work provides insight into how HCV is conceptualised by those it affects, exposing 
common expectations of chronic morbidity and altered life trajectories (Conrad et al., 2006; 
Paterson et al., 2006; Sutton and Treloar, 2007).  In contrast, the normalisation of HCV has also 
been reported from studies focused on people who inject drugs (PWID), revealing constructions of 
HCV infection as inevitable, unavoidable and ultimately part of the PWID identity (Harris, 2009; 
Roy et al., 2007; Wozniak et al., 2007).  Importantly, these insights into lived experience are 
situated within their sociocultural and temporal contexts, and have been repeatedly entwined 
with societal understandings of the challenging treatment available for HCV at the time, and an 
associated expectation of not being cured (Fraenkel et al., 2005; Groessl et al., 2008; Hill et al., 
2015; North et al., 2014; Swan et al., 2010). 
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Historically, the treatment of HCV was stubbornly reliant on the notoriously unpleasant 
immunomodulating agent interferon-α.  This drug, when combined with the nucleoside analogue 
ribavirin, comprised the dual therapy standard of care for HCV which endured throughout the 
2000s and into the early part of this decade.  These drugs needed to be taken for up to 48 weeks, 
demonstrated limited efficacy, and came with an extensive catalogue of both physical and 
neuropsychiatric side-effects (Manns et al., 2006).  Multiple studies exploring the experience of 
taking interferon-based regimens have repeatedly emphasised the severity of the treatment and 
the apprehension and fear it could produce (Hopwood and Treloar, 2005; Kinder, 2009; Sheppard 
and Hubbert, 2006).  The arduous and protracted nature of HCV treatment contributed towards 
the low rates of uptake recurrently reported (Grebely et al., 2009; Lazarus et al., 2014; Midgard et 
al., 2016), although multiple patient, provider and social factors have been identified as barriers to 
individuals accessing and completing a period of interferon-based therapy (Harris and Rhodes, 
2013; McGowan and Fried, 2012).  These barriers included poor adherence (and provider concerns 
of poor adherence), comorbidities (most notably psychiatric disorders), perceived and actual risks 
of reinfection and societal stigma (Grebely et al., 2013; McGowan and Fried, 2012), and were most 
acutely felt among groups of PWID.  The bulk of literature focused on the lived experience of HCV 
is predominantly situated within the context of this demanding, traumatic and inadequate 
treatment. 
 
Whilst the use of interferon-based dual therapy persists in many regions of the world, recent 
pharmacological advances have given some individuals, in mostly high-income nations, the 
potential to access new drugs that offer a highly effective and well-tolerated cure.  These 
interferon-free Direct Acting Antiviral (DAA) regimens offer substantially shorter treatment 
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durations, improved side-effect profiles and have demonstrated sustained virological response 
rates of over 90% (Asselah et al., 2016).  The dawn of this new era of HCV therapy has been 
heralded as a medical triumph (Chung and Baumert, 2014), although the global use of interferon-
free DAAs has been hampered by their considerable costs.  How such remarkable and rapid 
advances in the HCV treatment landscape may be influencing the experience of being HCV positive 
has so far received little attention.  To date, only three articles focused on the lived experience of 
HCV have utilised qualitative data collected during the interferon-free DAA era.  One of these 
articles focused exclusively on the Aboriginal community in Australia (Treloar et al., 2016), one on 
the experience of taking interferon-free treatment (Whiteley et al., 2016), and the other was 
limited to an examination of HCV-related fatigue (Zalai et al., 2016).  A broader contemporary 
understanding of how HCV is being experienced and perceived is therefore currently absent. 
 
In Scotland, during the timeframe of this study, a number of interferon-free DAA regimens were 
granted approval for use in clinical practice.  Access to these medications was restricted due to 
budgetary constraints, resulting in guidelines recommending concurrent provision of both 
interferon-free (typically a twelve week course of treatment) and interferon-based (up to 48 
weeks of treatment) therapies to those accessing care (Healthcare Improvement Scotland and 
NHS National Services Scotland, 2015).  Treatment rationing was dependent on a number of 
factors, including HCV genotype and the degree of liver disease.  Participants in the study recruited 
from specialist HCV care had been made aware of the treatments available and associated 
restrictions as part of routine care by their regular healthcare providers.  This study aims to 
recontextualise the lived experience of HCV within the context of this new therapeutic era.  In 
doing so, it seeks to consider the influence of an advancing therapeutic landscape on constructions 
of the illness.   
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METHODS 
Design 
A social phenomenological perspective underpins the study.  This sociological approach rotates 
phenomenology outwards, and postulates that the way humans construct their perspective on the 
outside world is not a purely individual process.  It emphasises the importance of the social world 
in establishing the meaning of phenomena, asserting the inter-subjective world as the foundation 
for human knowledge and experience (Shaw and Connelly, 2012).  Social phenomenological 
research explores the shared features of subjective experience that define a phenomenon’s 
meaning, focusing on the commonalities found in the life-worlds of more than one actor (Ajiboye, 
2012). 
 
The qualitative study design comprised of face-to-face, semi-structured interviews.  In total, 20 
participants with HCV were purposefully sampled from two locations; a hospital-based infectious 
diseases outpatient clinic, and a primary care doctors’ surgery, both situated within a large 
Scottish city.  The use of two recruitment sites aimed to select participants who had both engaged, 
and not engaged, with HCV specialist care.  Further characteristics of the purposive sample were 
identified in order to recruit a diverse group of participants, theorising that patterns emerging 
from great variation are of particular interest in capturing the shared dimensions of a 
phenomenon (Patton, 2015).  These characteristics were date of diagnosis, mode of acquisition, 
HCV treatment history and degree of liver disease, in addition to various sociodemographic 
factors.  The identification of these characteristics was based on a literature review conducted in 
the process of developing the study, and reflection by the research team on what may constitute 
‘common-sense’ categories (Mason, 2002).  The sample size of 20 was deemed sufficient to 
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capture this range of diverse characteristics, but not so large that detailed and nuanced analysis of 
the data would be compromised (Mason, 2002). 
 
Inclusion criteria consisted of being diagnosed with HCV for more than six months, aged 16 years 
or over and able to converse in English.  The requirements of the maximum variation sample were 
also taken into account as recruitment progressed.  Individuals who fulfilled the criteria were 
approached by their healthcare provider, and consent obtained for their details to be passed to 
the researcher (DW) if interest was shown in participating.  Records were not kept of how many 
individuals were approached but declined to participate.  A meeting was then arranged with the 
researcher, where the purpose of the study was explained, any questions answered, and written 
informed consent obtained. 
 
Data collection 
Interviews were conducted between June and December 2015, either within a suitable room at 
the outpatient clinic or doctors’ surgery, or at the participant’s home.  Interviews lasted between 
19 and 67 minutes, with a mean duration of 39 minutes.  An interview schedule was used to guide 
the conversation, which detailed four broad topic areas for discussion: the experience of 
diagnosis; the illness experience in everyday life; treatment knowledge and perception; and future 
outlook.  Within these topic areas, brief open-ended questions were used to initiate conversation 
e.g. “tell me about your life since diagnosis”, “what’s it like for you having hepatitis C?”, however, 
the interviews were conducted with a fluidity and responsiveness that allowed participants to talk 
about their experiences as they wished.  All interviews were conducted by DW, a registered nurse 
who had worked as a HCV nurse specialist between 2009 and 2013.  The interviews were audio-
recorded using an encrypted recording device, and transcribed verbatim by DW, during which any 
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information that may identify the participant was obscured from the narrative.  Following each 
interview a reflective account was written and added to field notes in a research diary.  Each 
participant was offered a £15 supermarket voucher in line with national guidelines, although three 
participants declined payment for their involvement in the study. 
 
Analysis 
Six phases of thematic analysis were used to guide the analytical process (Braun and Clarke, 2006).  
Each transcript was read repeatedly by two researchers (DW and AW) in order to ensure 
subsequent coding and theme development remained grounded in the participants’ narratives.  
Inductive coding was then conducted by DW using NVivo v.10 software to help manage the data.  
Whilst depicted as a linear process, the interviewing, transcribing and coding of the narratives 
occurred in parallel, with each activity informing the others.  This analytical process began 
following the initial interview, and as this iterative process continued, groups of codes were 
gradually combined, resulting in the formation of a number of sub-themes.  This cycle of analysis 
aided the identification of data saturation; coding of the final three transcripts aligned with the 
provisional sub-themes already developed.  These sub-themes were then combined into candidate 
themes, which were examined in relation to the corpus of data and the research diary.  During the 
analytical process, all four authors met regularly to probe and interrogate the evolving analysis, 
and to contest any preconceptions DW may have brought to the study due to his work history and 
association with the topic, consistent with the concept of bracketing.  Within social 
phenomenological research, bracketing demands that belief in the existence of the world as we 
know it is suspended, and encourages doubt that the world could be anything other than it 
appears (Schütz, 1967).  This ongoing peer review of the analysis aided rigour, and ensured the 
resulting themes were founded in the subjective life-worlds of the participants. 
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Ethical approval 
The study was considered and approved by the South East Scotland NHS Research Ethics 
Committee 01 (15/SS/0010) and by Edinburgh Napier University Research Integrity Committee. 
 
RESULTS 
Participants’ characteristics 
The characteristics of the sample are shown in table 1.  The participants were approximately equal 
by gender, predominantly white and ranged in age from 27 to 70.  The majority were unemployed 
and identified injecting drug use as their mode of HCV acquisition.  Few had previous experience 
of HCV treatment, with most reporting mild to moderate degrees of liver disease.  Despite 
recruitment attempts, only two participants were not currently engaged with specialist HCV 
services.  Analysis of the data resulted in three predominant themes: positioning hepatitis C; 
beyond a physical burden; and a new uncertainty. 
 
Positioning hepatitis C 
The first theme illustrates how hepatitis C was understood within wider sociocultural, medical and 
politico-economic contexts.  Participants described reactions to their medical diagnosis of HCV 
that positioned it within the context of their lives at the time.  For example, for those who situated 
their diagnosis within a period of drug use, familiar reactions of shock, fear and anguish appeared 
mitigated by a perception that they had put themselves at risk: 
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…but aye, it was, it was pretty devastating, but the same time I sort a’ had that attitude 
well ken what, you knew what you were doing at the time, you knew the risks you were 
taking, things we do a’ get stoned eh? 
 
 (Female, diagnosed 2013, degree of liver disease unknown) 
 
Similarly, for participants who reported a pre-existing HIV infection, diagnosis of a further blood 
borne virus was portrayed as holding little significance, often negating such emotional reactions 
entirely: 
 
I was actually, no’ numb or anything, jus’ indifferent, because of my HIV status, I jus’ 
thought oh that’s another disease I’ve got (…) ’cause, I always assumed that HIV was 
gonna kill me anyway. 
 
(Male, diagnosed 2004, non-cirrhotic) 
 
Whilst the participants’ sociocultural and biographical circumstances shaped their reactions, the 
timing of the diagnosis within the context of HCV treatment evolution appeared to have little 
influence.  Approximately equal numbers of participants were diagnosed before and after the start 
of the DAA era in 2011, yet narratives around response to diagnosis did not reflect any recognition 
of these pharmacological developments.  A discourse which comprised socially contextualised 
distress, disbelief and depression remained critical to the participants’ experiences of HCV 
diagnosis in the era of DAAs.  Indeed, some of the most vivid and striking accounts of intense 
reactions to diagnosis came from participants who received the news most recently: 
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I remember going to the nurse, and err, my mum was with me, an’ I remember they read 
out the hep B, hep A blah blah blah, AIDS an’ all that, an’ [pauses] an’ they said hep C – 
positive [pauses] an’ [pauses] I was, I jus’ [blows out air] God, blanked out, I, I, I went into 
shock, ‘cause all I remember hearing was, my mum going “oh my God” and they ended up 
having to go an’ get the doctor because I had went into shock... 
 
(Female, diagnosed 2014, non-cirrhotic) 
  
This brief discussion of diagnosis provides insight into how participants initially positioned and 
contextualised the disease within their testimonies.  However, such reactions were often modified 
and revised as they lived with the disease and came to understand it from a new perspective.  
Post-diagnosis, participants often framed their experience of living with HCV in terms of how they 
were faring in relation to others who were HCV positive, whether personally known to them or 
not. The majority of participants recounted a perception that HCV was having less impact on their 
life than it was for other individuals, and a broad perception pervaded that ‘others have it worse’: 
 
M: Hmmm, I think, compared to a lot of people with hep C, I have been really, really 
lucky. 
 
I: Why? 
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M: It’s not really had that much of an impact on my life day-to-day, you know what I 
mean? Compared to people with this an’ that, I can see, no it hasn’t.  I’m very, very 
lucky. 
 
(Female, diagnosed 1997, non-cirrhotic) 
 
 
…I think I’ve been a little bit lightweight here because, you know, there’s a lot of people 
out there that are, really in much worse chance with hep C than I have, so I’m, you know, 
considering myself to be quite fortunate… 
          
(Male, diagnosed 2012, non-cirrhotic) 
 
A major contributing factor to this perception was often the relative health of their liver compared 
to others, which began to fracture their understanding of HCV as a single disease.  For those who 
engaged with HCV services post-diagnosis, the results of blood tests and scans fostered a 
recognition that the diagnostic HCV label disguised a range of illness trajectories and outcomes.  
Hepatitis C could be both a malignant killer and a benign inconvenience: 
 
…and I have [the ultrasound scan] done today, and according to the person who did it, 
everything seems to be normal, no damage at all, which I feel like I won the lottery!  I 
know many people die of hepatitis C in the past, and it’s not that easy to cure, or some 
people have more complication than other, but to be honest with you, I feel relief knowing 
that there is no damage in the liver. 
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(Male, diagnosed 2015, non-cirrhotic) 
 
Examples of feeling fortunate were also present amongst the narratives of those with more 
advanced liver disease, although these tended to be positioned in relation to their own mortality, 
rather than other people.  Despite being cirrhotic, a diagnosis of HCV had given one participant the 
impetus to stop drinking alcohol, and his understanding of HCV therefore included protective and 
beneficial elements: 
 
…over three years now I’ve been sober, d’y’know, an’ my liver’s knackered [laughs] an’ it 
kind a’ makes you feel wow – what would I have been like if [pauses] - I’d be dead.  I 
would’ve been dead. Wow.  Y’know, it’s like there’s no way I’d have survived that, nah, 
err, so you’re thinking well I’m very, very lucky… 
 
(Male, diagnosed 2005, cirrhotic) 
 
By engaging in social comparison, the participants fractured HCV into degrees, producing a 
continuum of illness, rather than a uniform disease.  There were those who ‘had it worse’ or who 
were ‘more in need’.  This understanding was further enforced as participants confronted the 
inequality of access to new HCV treatments, and came to understand that their position on the 
illness continuum had direct consequences for their entitlement to new medications.  Whilst a 
healthier liver conferred a positive prognosis, it could also mean denial to the most effective 
treatments and could therefore be recognised as a double-edged sword: 
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…an’ then today I’ve been told that I dunnae fit the criteria, because my liver’s quite 
healthy which is, a bit of a’ shock but hey, wait a minute, you want me a’ go to start using 
[drugs]?  Or you want me to, y’know, make mysel’ worse so I could, get an easier 
[treatment]? 
 
(Male, diagnosed 2000, non-cirrhotic) 
 
Although this reaction was echoed by a small number of other participants, the denial of access to 
new HCV drugs was more commonly embraced as a positive endorsement of liver health.  New 
treatments were associated with a greater degree of liver damage, therefore not being prioritised 
further affirmed and corroborated the reassuring test results previously received:   
 
…after doing the test [mimes fibroscan®], I felt a bit relieved in the sense that err, even 
though I’ve had hepatitis for a long time, and err, with all the alcohol I’ve been drinking, 
the damage was not that bad that I should be put on the priority [treatment].  So it was a 
bit comforting for me. 
 
(Female, diagnosed 2005, non-cirrhotic) 
 
Treatment rationing was accepted by the majority of participants as an undisputed clinical 
necessity, with distributive justice discussed in terms of merit, as well as need.  These narratives 
positioned people as less deserving of treatment if they were perceived as likely to waste 
resources due to ongoing drug and/or alcohol use: 
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I do believe that if they’re still drinking an’ that they shouldn’ae be getting the treatment.  
It’s no’ because I dunnae want them a’ get better, it’s jus’ ‘cause they’re wasting resources 
an’ money.  It’s stupid, when you’re getting a drug that costs so much, an’ really, if you’re 
jus’ gonna keep taking, drinking, ken, fucking up… 
 
(Male, diagnosed 2005, non-cirrhotic) 
 
 
Concurrent narratives of distributive justice by need and merit could sit side-by-side within a single 
participant’s account, with little sense of conflict.  A complex social understanding of HCV 
treatment allocation became evident, with individuals balancing need, merit and other 
idiosyncratic factors against a perception of their own position on the HCV illness continuum.  For 
the most part, such narratives were underscored by an unquestioning tolerance and acceptance of 
treatment rationing and inequality. 
 
Beyond a physical burden 
The second theme reveals how the participants firmly located the emotional burden of a somatic 
disease as their predominant concern.  The physical aspect of HCV infection was absent from 
almost half of the participants’ testimonies, and where it did occur, the discourse of physical 
disruption was rarely emphasised as particularly significant.  Reduced energy and general fatigue 
were mentioned anecdotally, and framed by most as a manageable and slight inconvenience, 
rather than a life-changing condition: 
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I jus’ feel [pauses] a little bit drained, but not sick, sick.  My body’s jus’ went through like a, 
a big deal, y’know, but I don’t feel like - oh my God, y’know, I’m dying, I’m dying… 
(Female, diagnosed 2014, non-cirrhotic) 
 
I dunnae focus much on it [HCV], an’ then when I do think about it, I think well, it’s no’ like 
it changes my lifestyle or, y’know there’s things that I cannae do, I can still live a normal 
life… 
(Female, diagnosed 2008, non-cirrhotic) 
 
Whilst the physical burden of HCV formed a weak and insubstantial pattern within the data, the 
impact on participants’ emotional wellbeing was richly constructed and comprised multiple 
strands.  Hepatitis C was framed as an illness that caused a persistent disquiet and underlying 
worry, which participants’ attempted not to dwell upon or brood over: 
 
I try not to obsess about it, you know, it’s kind of running away in the back of your mind 
the whole time but I try not to, you know, let it affect me too much… 
(Male, diagnosed 2012, non-cirrhotic) 
 
The lack of physical impact from HCV could contribute towards this enduring worry.  Whilst some 
participants used the lack of symptoms to try and block HCV from their thoughts, others found 
being unable to monitor the effect HCV may be having on their body unsettling.  The fear of 
transmitting the virus to others was also framed as a significant source of anxiety, with specific 
fears over transmitting HCV to children and partners commonplace within the narratives: 
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I struggle wi’ it, I struggle wi’ jus’ being around people an’, an’ jus’ knowing that I could 
put them at risk, it’s jus’ a worry, I worry, a day a’ day worry… 
 
(Female, diagnosed 2013, degree of liver disease unknown) 
 
Since I got divorced, I jus’ thought, nah, I can’t.  Y’know, an’ that’s been over, I don’t know, 
seven year?  I jus’ thought well you cannae have sex again, ‘cause you’ll end up likes, 
giving it to somebody else. 
 
(Male, diagnosed 2005, cirrhotic) 
 
Whilst onward transmission and fears of insidious disease contributed to the emotional burden of 
HCV, this thematic strand was most evident within the discourse surrounding stigma.  Words such 
as ‘dirty’, ‘branded’ and ‘leper’ were persistently employed by participants to describe how HCV 
made them feel, with one individual’s account describing the physical manifestation of such 
intense emotions: 
 
Once, a couple a’ months ago, thinking about it, I start scratching, I start – oh, I’m no’ 
bothered brushing my teeth today, I dunnae need to do it, what’s the point when I’ve got 
this? 
(Male, diagnosed 2015, cirrhotic) 
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The narratives drew frequent associations between such internalised stigma, and predominant 
societal attitudes towards drug use and PWID.  The participant went on to describe how his 
physical reaction had been related to his association of HCV with this socially vilified group: 
 
I think most people jus’ treat hep C as just a dirty, dirty, disgusting virus, an’ I think most 
people jus’ think you’re a bloody drug user.  That’s the way most people think. 
 
(Male, diagnosed 2015, cirrhotic) 
 
Most participants sought to manage the stigma associated with HCV by strategically and cautiously 
selecting their confidantes.  However, a small number tackled the issue of disclosure head-on by 
announcing their HCV status widely.  It was better to be open and honest with everyone than 
contend with the complexities of selective disclosure.  Participants justified this uncompromising 
approach by emphasising the personal gain to be achieved (“I tell people right up front ‘cause I 
dinnae wanna waste time wi’ somebody who’s gonna be my fair-weather pal” [Male, diagnosed 
2004, non-cirrhotic]), and by citing altruistic intentions.  One woman positioned herself as a 
cautionary tale: 
 
I’m straight up with people, y’know, because if I can sort a’ make someone think y’know, 
hey, I’m no’ away a’ do that, then, yeah, I’ll, I’ll, I tell people. 
 
(Female, diagnosed 2014, non-cirrhotic) 
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Whilst the participants constructed narratives rich in anxiety concerning anticipated stigma, and 
replete with accounts of internalised shame, discussion of first-hand experiences of stigma were 
often hard to pin down.  Sporadic reports detailing explicit and overt acts of stigmatising 
behaviour were the exception, rather than the rule: 
 
…these friends, they always used to give you a cuddle cheerio an’ now they don’t do that 
y’know, an’ I don’t think they realise how much that hurts, y’know to think that that’s 
what they could catch. 
 
(Female, diagnosed 1991, cirrhotic) 
 
Whilst this may imply that the stigma felt by participants was disproportionate to the level of 
stigma found within society, the narratives also alluded to the passive and covert nature of much 
stigmatising practice.  For example, one participant related how a chance encounter with an 
acquaintance revealed a concealed act of discrimination that may otherwise have gone 
undetected: 
 
…there’s a woman used a’ go a’ the [community centre], now she’s got a cup in the 
[community centre] – now I never told her I’d hepatitis C, ‘cause I, I dunnae use or that wi’ 
her - she’s standing at the bus stop - “aye, fuckin’ I’m gonna get my cup ‘cause, what if 
they’ve got hepatitis C”… 
 
 (Female, diagnosed 2013, degree of liver disease unknown) 
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The emphasis on the emotional burden of HCV within the narratives produced a discourse that 
also highlighted the importance participants placed on support.  Whilst family and friends were 
commonly positioned as central to preserving emotional welfare, speaking to someone ‘outside 
the family’, who had personal experience of living with HCV was particularly valued: 
 
…but the groups an’ everything that I went to, oh, they were amazing.  Other people 
talking about what they go through, erm, an’ you’re no’ sort a’ looked at as being 
different fae anybody else…   
 
(Female, diagnosed 2009, non-cirrhotic) 
 
A new uncertainty 
The final theme explores how uncertainty was etched throughout the collected narratives, and the 
prominence of uncertainty and scepticism in understandings of new HCV therapies.  The concept 
of uncertainty was often established during discussion of how HCV was understood at the time of 
diagnosis:   
 
…and [my GP] was like, can you sit down, an’ I’m like I’m just in a’ get my prescription, an’ 
she was like no I need a’ speak to you, an’ I didn’t even know what hepatitis C was, I was 
like, is this like HIV, is this gonna kill me?  
 
(Female, diagnosed 2012, non-cirrhotic) 
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Uncertainty was not limited to retrospective reflections on diagnosis, but pervaded across the 
illness trajectory.  For example, those with no history of injecting drug use repeatedly expressed 
uncertainty as to how HCV had been acquired, and nearly all participants voiced concerns and 
confusion surrounding the silent advance of liver disease: 
 
…you don’t know how it could progress, is it changing?  How fast is it progressing?  Even 
though the appointments are six months apart what’s happening in-between?  You think 
well, things could change an’, oh, will I know about it? 
 
(Female, diagnosed 1997, non-cirrhotic) 
 
In addition to these familiar refrains, uncertainty was also prominent in the participants’ discourse 
surrounding HCV therapies.  Understandings of new treatment options were vague and 
ambiguous, with participants expressing confusion regarding the plethora of new treatment 
regimens becoming available: 
 
…there’s jus’ a lot a’ misinformation about what treatment drugs people were on, 
whether it be first, the first treatment that came out, or the second one, or the newer one, 
because they’re coming out so fast… 
 
(Male, diagnosed 2013, non-cirrhotic) 
 
Such confusion contributed to the cautious reception that often greeted these new HCV therapies.  
A perception that individuals would respond differently to the drugs based on unspecified innate 
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factors was also repeatedly voiced, and a discourse emerged that emphasised scepticism and the 
importance of experience over blind faith: 
 
…‘cause everything affects everybody differently, everyone’s different, every drug affects 
everybody differently as you know, err, it, it might be, I might be jus’ one of these people 
err, these awkward, err buggers, it doesn’t agree with. 
 
(Male, diagnosed 1997, cirrhotic) 
 
For those co-infected with HIV, HCV treatment uncertainties were rooted in their experience of 
failed HIV regimens and unforeseen side-effects.  Despite the reassuring and optimistic rhetoric 
espoused by healthcare professionals, new HCV therapies were unknowns, which needed to be 
closely monitored: 
 
I think [HCV treatment] would be a matter of me being in [the hospital] for a few days, to 
see that it’s settling down ok, then let me out and come back an’, y’know, just keep a good 
eye on me. 
 
 (Female, diagnosed 1991, non-cirrhotic) 
 
The provision of written information by healthcare staff on the practicalities of taking the drugs 
did little to challenge the treatment uncertainty.  Although one participant was given literature on 
how to take his drugs, he still felt he knew little about them: 
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I, I know nothing about this stuff, all I know is err, I’ve been err, described on, how to take 
it, err, an’ how many times to take it, y’know, dosage, erm, frequency of dosage an’ all 
that, all that bumf.   
 
(Male, diagnosed 1997, cirrhotic) 
 
During the study, the hospital-based recruitment site hosted two phase III randomised controlled 
trials (RCTs) for new HCV drugs, and an awareness of clinical trials was therefore common among 
the participants.  However, the perception of HCV treatments as ‘trial drugs’ was not limited to 
RCTs, but more commonly applied in blanket fashion to all DAAs which were available in clinic.  A 
couple of participants who were not considering RCTs still referred to themselves as “guinea pigs”, 
emphasising the novelty and nascent nature of the regimens.  A perception persisted that despite 
being licensed, these drugs were still largely unknowns: 
 
I ken they’ve obviously done clinical tests an’ that, but, that’s in a sort a’ controlled 
environment, but when you’re talking about people who’re, normal people who’re 
suffering from depression an’ drug problems an’ all a’ that, y’know what I mean, that kind 
a’ goes oot the window, that clinical test… 
 
(Male, diagnosed 2004, non-cirrhotic) 
 
The uncertainty around access to new therapies, and contemporaneous use of interferon-based 
regimens alongside interferon-free options created a sense of conflict for participants.  Decisions 
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about HCV treatment were often framed as a trade-off: live with the virus and wait indefinitely for 
access to improved therapies, or take an interferon-based option now: 
 
…if [the doctor] says there’s a chance we could gi’ you this new treatment, but you’ll have 
to wait two year or three year, then I would wait y’know, but if they says no that’s no’ 
gonna happen, then I would jus’ have to deal wi’ it an’ get on wi’ [the interferon]… 
 
(Female, diagnosed 2008, non-cirrhotic) 
 
Whilst some participants eschewed the interferon option, in favour of an uncertain wait, others 
embraced whatever treatment regimen was offered.  This latter approach was underpinned by the 
protracted and challenging journeys to treatment that many participants described, and which 
created a sense that they had already waited long enough.  A prevailing sense of wanting to be 
free of HCV at any cost developed for a few participants, with a willingness to accept the ordeal 
and disruption of interferon-based regimens: 
 
I mean, the end game is, erm, I want a’ go through the treatment, if, if it has to be a six 
month one that’ll have to be, I mean I’ll, have to grin an’ bear it eh?  
 
(Male, diagnosed 2000, non-cirrhotic) 
 
DISCUSSION 
A qualitative focus on HCV has long provided valuable insight into the experience of those living 
with the virus, and their understanding of the illness (e.g. Miller et al., 2012; Treloar and Rhodes, 
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2009).  However, the wealth of research in this area must be viewed within its historical context, 
as the majority of studies were conducted during the era of arduous, and poorly efficacious, 
interferon-based therapy.  Over the last five years, rapid pharmacological advances have 
transformed the prospects of those undergoing HCV treatment in Scotland, and whilst access to 
new interferon-free DAA regimens has been restricted, significantly improved therapeutic options 
for HCV now exist (Chung and Baumert, 2014).  This study has sought to contextualise the lived 
experience of HCV within this modern era of therapy, and in doing so allow exploration of whether 
constructions of HCV have been disturbed by the arrival of a fast, effective and tolerable cure. 
 
The complex emotional burden of HCV was writ large throughout these contemporary narratives 
within familiar refrains that have dominated previous research.  For example, reactions at 
diagnosis and the tenacity of stigma resonate with studies conducted during the interferon era 
(e.g. Butt et al., 2008; Conrad et al., 2006; Fraser and Treloar, 2006; Hill et al., 2015; Rhodes and 
Treloar, 2008) and speak to the lack of influence a rapidly improving cure has yet to exert on 
emotional spheres of illness.  Biomedical attention on treating and curing the somatic disease has 
decontextualized HCV from peoples’ lives, and, to date, has failed to concurrently address its 
wider sociocultural impact.  The persistence of societal stigma continues to incite anxiety, shame 
and fear in those infected, perpetuating the spoiled and discreditable label of HCV (Treloar et al., 
2013), resulting in an unyielding and obstinate emotional burden of illness. 
 
Beliefs about the illness course and duration also appeared little altered from previous studies as a 
discourse of chronicity wove throughout the themes.  ‘Positioning HCV’ was underpinned by an 
assumption that participants’ were at a particular point on an illness continuum, and that HCV 
presented an advancing threat with degrees of severity and diverse trajectories.  Of course, 
 
 
26 
 
understandings of HCV as a potentially progressive disease do not automatically equate with an 
expectation that long-term effects would be directly experienced.  Indeed, participants positioning 
their experience in relation to others may simply be viewed as a discursive strategy, used 
protectively to assess their own situation in a better light.  The uncertainty with which DAA 
regimens were framed, however, supports a notion that voicing concerns of illness chronicity was 
not solely a strategic device.  These effective, well-tolerated drugs, feted and lionised within 
medical discourse (Chung and Baumert, 2014; Pawlotsky et al., 2015) were not met with the same 
chorus of adoration by the participants.  Rather, narratives of caution, confusion and uncertainty 
emerged, emphasising a vague and ambiguous grasp of HCV treatment evolution.  The 
participants’ understandings and belief in this new era of therapy were too untried and untested 
to challenge the well-founded cultural memory of HCV as a chronic condition (Paterson et al., 
2006; Sutton and Treloar, 2007), echoing reports of a cultural lag described by Whiteley et al. 
(2016). 
 
A cautious framing of the effectiveness of these new medications, and beliefs surrounding the 
likelihood of gaining access to the drugs, also constructed an understanding that participants 
lacked control over their illness trajectory.  An implicit acceptance of the health inequality status 
quo underpinned the participants’ discourse, as they constructed narratives around the 
assumption that HCV treatment rationing was an absolute, and adapted their understanding to 
accommodate that assumption, rather than challenge it.  This instinctive tolerance of health 
injustice speaks to theoretical arguments that suggest an individuals’ capability to be healthy can 
be constrained by their physical and social environments, as well as the political, economic, 
cultural and legal determinants of those environments (Venkatapuram, 2011).  It resonates with 
the lack of entitlement and therapeutic citizenship reported within HCV communities over the 
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years (Rhodes et al., 2013; Wolfe et al., 2015), and reinforces perceptions that control over the 
illness lies in political and economic domains, rather than in the hands of healthcare providers or 
the individuals themselves. 
 
This study has a number of limitations.  The participants were a small group from one city in 
Scotland, and their experience was located within a particular social, cultural and political context.  
However, the insights gained speak to wider populations of HCV positive individuals within high-
income nations with restricted access to interferon-free DAAs.  Despite recruitment attempts, the 
sample was also mainly composed of individuals who were already accessing specialist HCV care, 
who may have been more conversant with developments in HCV treatment than those who do not 
engage with services.  The scarcity of individuals recruited from without the hospital site also 
contributed to the relative dearth of those who identified as current PWID. 
 
CONCLUSION 
This exploration of the contemporary lived experience of HCV has emphasised how a rapidly 
improving treatment has so far failed to successfully challenge inter-subjective perceptions of the 
illness.  How long this situation may endure is unknown.  Within high-income nations, the social 
perception of HCV may naturally evolve as the costs of interferon-free DAAs reduce, and their use 
proliferates.  However, in the short- to medium-term, understandings of HCV as a long-term, life 
altering and emotionally draining illness continue to impact how individuals respond to and make 
sense of the infection.  The new therapeutic era of HCV may be constrained by inter-subjective 
perceptions of the illness as a chronic, emotionally scarring condition over which there is little 
control. 
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RELEVANCE TO CLINICAL PRACTICE 
Whilst the advent of interferon-free DAA treatments has been widely eulogised, this study 
exposes how their arrival has yet to effectively challenge societal constructions of HCV.  The 
perception and understanding of HCV has previously been demonstrated to adversely impact on 
the prevention of transmission, testing and diagnosis, engagement with care and access to 
treatment (Harris et al., 2016; Miller et al., 2012; North et al., 2014; Sublette et al., 2014; Treloar 
et al., 2013), and as these long-held and deeply-rooted perceptions endure, interferon-free DAA 
regimens are unlikely to realise their full potential.  For nurses working within the field of HCV, this 
poses challenges to engaging HCV positive individuals in appropriate care and treatment 
pathways.  Effective drugs are only part of the solution to addressing the HCV global health 
epidemic; nurses must also acknowledge and challenge perceptions of the disease. 
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Table 1: Demographic information for the 20 participants.  All information was self-reported 
during their interview. 
Engagement with specialist HCV care Engaged 18 
 Not engaged 2 
Date of diagnosis Pre-2011 12 
 2011 and after 8 
Mode of acquisition Injecting drug use 13 
 Other 7 
HCV treatment history Previous treatment 3 
 No previous treatment 17 
Gender Male 11 
 Female 9 
Ethnicity White British 18 
 Other 2 
Age <39 5 
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 40-49 4 
 50-59 9 
 >60 2 
Degree of liver disease Pre-cirrhotic 13 
 Cirrhotic 5 
 Unknown 2 
HIV coinfection 
 
HIV positive 
HIV negative/unknown 
5 
15 
Employment status Paid employment 6 
 Unemployed 13 
 Retired 1 
Living arrangements Lives alone 8 
 Lives with family 12 
 
 
 
